Richard Aranda

4.5k total citations · 2 hit papers
37 papers, 3.2k citations indexed

About

Richard Aranda is a scholar working on Rheumatology, Genetics and Immunology. According to data from OpenAlex, Richard Aranda has authored 37 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Rheumatology, 12 papers in Genetics and 11 papers in Immunology. Recurrent topics in Richard Aranda's work include Inflammatory Bowel Disease (10 papers), Eosinophilic Esophagitis (7 papers) and Liver Diseases and Immunity (7 papers). Richard Aranda is often cited by papers focused on Inflammatory Bowel Disease (10 papers), Eosinophilic Esophagitis (7 papers) and Liver Diseases and Immunity (7 papers). Richard Aranda collaborates with scholars based in United States, Belgium and Canada. Richard Aranda's co-authors include Jean‐Claude Becker, Tracy Li, Maxime Dougados, Isaac Nuamah, Michael E. Luggen, Michael Schiff, Mark C. Genovese, J. Box, Kannan Natarajan and Yvonne Sherrer and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.

In The Last Decade

Richard Aranda

37 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition

2005 920 citations Mark C. Genovese, Jean‐Claude Becker et al. New England Journal of Medicine profile →
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

2016 360 citations William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Richard Aranda

Since Specialization

Citations

This map shows the geographic impact of Richard Aranda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Aranda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Aranda more than expected).

Fields of papers citing papers by Richard Aranda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Aranda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Aranda. The network helps show where Richard Aranda may publish in the future.

Co-authorship network of co-authors of Richard Aranda

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Aranda. A scholar is included among the top collaborators of Richard Aranda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Aranda. Richard Aranda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Efficacy and Safety of RPC4046, an Anti-Interleukin-13 Monoclonal Antibody, in Patients With Eosinophilic Esophagitis: Results From the Open-Label Extension of the HEROES Study 2019 ·Journal of Allergy and Clinical Immunology ·Evan S. Dellon, Margaret H. Collins, Yehudith Assouline-Dayan, Larry Evans, Sandeep K. Gupta, Alain Schoepfer, Alex Straumann, Ekaterina Safroneeva, (unknown), Allan Olson, Gregory J. Opiteck, Richard Aranda, Ikuo Hirano	7
2	Safety and Efficacy of Long-term Treatment With Ozanimod: An Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis - TOUCHSTONE Extension 2-Year Follow-up 2017 ·The American Journal of Gastroenterology ·William J. Sandborn, Brian G. Feagan, Geert D’Haens, Stephen B. Hanauer, Douglas C. Wolf, Séverine Vermeire, Subrata Ghosh, (unknown), Darryl Penenberg, (unknown), Richard Aranda, Allan Olson	5
3	Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis breakdown → 2016 ·New England Journal of Medicine ·William J. Sandborn, Brian G. Feagan, Douglas C. Wolf, Geert D’Haens, Séverine Vermeire, Stephen B. Hanauer, Subrata Ghosh, Heather Smith, Matthew Cravets, Paul Frohna, Richard Aranda, Sheila Gujrathi, Allan Olson	360
4	Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study 2013 ·Gut ·Lloyd Mayer, William J. Sandborn, (unknown), Karel Geboes, Robert Hardi, Michael Yellin, Xiaolu Tao, (unknown), Luisa Salter–Cid, Sheila Gujrathi, Richard Aranda, Allison Luo	119
5	Longterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy 2012 ·The Journal of Rheumatology ·Mark C. Genovese, Michael Schiff, Michael E. Luggen, Manuela Le Bars, Richard Aranda, Ayanbola Elegbe, Maxime Dougados	52
6	Abatacept for Crohn's Disease and Ulcerative Colitis 2012 ·Gastroenterology ·William J. Sandborn, Jean‐Frédéric Colombel, Bruce E. Sands, Paul Rutgeerts, Stephan R. Targan, Remo Panaccione, Brian Bressler, K. Geboes, Stefan Schreiber, Richard Aranda, Sheila Gujrathi, Allison Luo, Yun Peng, Luisa Salter–Cid, Stephen B. Hanauer	111
7	Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study 2012 ·Annals of the Rheumatic Diseases ·Edward Keystone, Joel M. Kremer, Anthony S. Russell, J. Box, Carlos Abud‐Mendoza, Mario Alberto Garza‐Elizondo, Allison Luo, Richard Aranda, I. Delaet, René Swanink, Sheila Gujrathi, Michael E. Luggen	43
8	Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial 2011 ·Annals of the Rheumatic Diseases ·Joel M. Kremer, Anthony S. Russell, Paul Emery, Carlos Abud‐Mendoza, Jacek Szechiński, René Westhovens, Tracy Li, Xianhuang Zhou, Jean‐Claude Becker, Richard Aranda, Charles Peterfy, Harry K. Genant	112
9	Targeting lymphocyte co-stimulation: From bench to bedside 2010 ·Autoimmunity ·Nathan Felix, Anish Suri, Luisa Salter–Cid, Steven G. Nadler, Sheila Gujrathi, M Corbo, Richard Aranda	26
10	Consistent Safety and Sustained Improvement in Disease Activity and Treatment Response over 7 Years of Abatacept Treatment in Biologic-Naive Patients with RA 2010 ·Anthony Russell, René Westhovens, (unknown), Paul Emery, Tracy Li, Richard Aranda, Jean-Claude Becker, (unknown), Maxime Dougados	17
11	A Randomized, Placebo-Controlled Trial of MDX-1100, an Anti-IP-10 Antibody, for Moderately to Severely Active Ulcerative Colitis 2010 ·Gastroenterology ·Lloyd Mayer, William J. Sandborn, (unknown), (unknown), Xiaolu Tao, (unknown), Sheila Gujrathi, Richard Aranda, Allison Luo	7
12	649 A Randomized Placebo-Controlled Trial of Abatacept for Moderately-to-Severely Active Crohn's Disease (CD) 2010 ·Gastroenterology ·Stephen B. Hanauer, William J. Sandborn, Bruce E. Sands, Paul Rutgeerts, Remo Panaccione, Brian Bressler, (unknown), René Swanink, Richard Aranda, Allison Luo	8
13	Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study 2009 ·The Journal of Rheumatology ·René Westhovens, Joel M. Kremer, Larry W. Moreland, (unknown), Anthony S. Russell, Tracy Li, Richard Aranda, Jean‐Claude Becker, (unknown), Maxime Dougados	93
14	Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition breakdown → 2005 ·New England Journal of Medicine ·Mark C. Genovese, Jean‐Claude Becker, Michael Schiff, Michael E. Luggen, Yvonne Sherrer, Joel Kremer, C. Birbara, J. Box, Kannan Natarajan, Isaac Nuamah, Tracy Li, Richard Aranda, David Hagerty, Maxime Dougados	920
15	Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve‐month results of a phase iib, double‐blind, randomized, placebo‐controlled trial 2005 ·Arthritis & Rheumatism ·Joel M. Kremer, Maxime Dougados, Paul Emery, Patrick Durez, Jean Sibilia, William Shergy, Serge Steinfeld, Elizabeth A. Tindall, Jean‐Claude Becker, Tracy Li, Isaac Nuamah, Richard Aranda, Larry W. Moreland	351
16	Mesenteric B cells centrally inhibit CD4⁺T cell colitis through interaction with regulatory T cell subsets 2005 ·Proceedings of the National Academy of Sciences ·Bo Wei, Peter Velázquez, Olga Turovskaya, (unknown), Richard Aranda, Mitchell Kronenberg, Lutz Birnbaumer, Jonathan Braun	148
17	Maternal Adaptive Immunity Influences the Intestinal Microflora of Suckling Mice 2004 ·Journal of Nutrition ·(unknown), (unknown), Jiafang Wang, José Luis Vela, Martı́n G. Martı́n, (unknown), Richard Aranda	18
18	Role of passive and adaptive immunity in influencing enterocyte-specific gene expression 2003 ·American Journal of Physiology-Gastrointestinal and Liver Physiology ·(unknown), Jiafang Wang, (unknown), José Luis Vela, (unknown), (unknown), (unknown), (unknown), Richard Aranda, Martı́n G. Martı́n	36
19	Recombinant human keratinocyte growth factor (rHuKGF) ameliorates disease symptoms in both the DSS and CD45RB hi cell transfer murine models of inflammatory bowel disease (IBD) 2001 ·Gastroenterology ·Fergus R. Byrne, Catherine L. Farrell, Richard Aranda, (unknown), (unknown), Silvia Flores, Dimitry M. Danilenko, David L. Lacey, Giorgio Senaldi	2
20	Generation of Intestinal Mucosal Lymphocytes in SCID Mice Reconstituted with Mature, Thymus-Derived T Cells 1998 ·The Journal of Immunology ·Victoria Camerini, Beate C. Sydora, Richard Aranda, (unknown), (unknown), William H. McBride, Mitchell Kronenberg	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact